At the close on September 18, 2026, Aurobindo stock ended the U.S. session slightly lower, underperforming a marginally ...

Pondicherry may be known for its French-colonial charm, Auroville, breezy beaches and effortlessly cool cafés, but there is ...

The launch marks Aurobindo Pharma's entry into the US inhalation market and expands its complex generics portfolio beyond conventional oral solid formulations ...

After a rough regulatory start to the year, India’s Aurobindo Pharma is charting plans for growth. The Hyderabad-based generics juggernaut will plow 3 billion Indian rupees (about $37.7 million) into ...

Aurobindo Pharma receives U.S. FDA approval for a generic asthma inhaler, expanding into complex respiratory therapies.

Aurobindo Pharma said the US FDA inspection of Unit-IV of its wholly owned subsidiary Apitoria Pharma concluded with zero ...

Hyderabad: Aurobindo Pharma Limited has announced the completion of a United States Food and Drug Administration (USFDA) ...

Aurobindo's Lannett launches a generic version of GSK’s Advair Diskus in the U.S., expanding its inhalation product portfolio.

Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Aurobindo Pharma's fair value estimate has been revised from ₹1,379.96 to ₹1,519 ...

Patients with pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate have a new generic treatment option available. The Food and Drug ...

Aurobindo Pharma gains USFDA approval for a generic asthma inhaler, marking its entry into complex respiratory therapies.